welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
study id #: NCT01245816
condition: Familial Adenomatous Polyposis
status: withdrawn
purpose:The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).
intervention:
Drug: Eflornithine plus Sulindac
Drug: Eflornithine plus Placebo
Drug: Sulindac plus Placebo
expertly curated content related to this topic
-
Three Cases with Familial Adenomatous Polyposis Diagnosed as having Malignant Lesions in the Course of a Long-Term T...The inhibitory effect of n-3 polyunsatur...
-
Diagnosis, Surveillance, and Treatment Strategies For Familial Adenomatous Polyposis: Rationale and UpdateFamilial adenomatous polyposis is charac...
-
Regression of Colonic Adenomas After Treatment with Sulindac in Familial Adenomatous Polyposis: A Case with a 2-Year...Familial adenomatous polyposis (FAP) is ...
-
Chemoprevention of Colorectal NeoplasiaBACKGROUND : Colorectal cancer is a comm...
-
Revealing the Power of the Rare Disease Community With State-of-the Art Collaborative, Trustworthy, Digital Educatio...The growth of online communities in ...
-
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polypos...This randomized phase II trial studies h...
-
CEO Jeff Jacob Talks About FAP Trial (Familial Adenomatous Polyposis)https://www.youtube.com/watch?v=abPLjl6B...